Friday, April 26, 2019 - Insilico Medicine, a biotech company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Pioneers '19 in Vienna, May 10.
Artificial intelligence (AI) has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments.
At Insilico, AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
"We look forward to welcoming Alex at our flagship event in Vienna for the second time and hearing more about his pioneering work in the HealthTech field," says Oliver Csendes, Pioneers CEO. "Healthy longevity is a main theme of this year's event, which will take our guests on a technological walk through life, and we're proud to welcome experts like him to support us in going beyond the tech hype."
"We are happy to present our latest research at the Pionners'19, which gathers the leading longevity leaders. The topic of healthy longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
Pioneers '19 is the ultimate meeting point for 2500 bold, pioneering entrepreneurs to look into the future and beyond. A global community of selected startups, executives and investors join forces under the roof of the 500-year-old Hofburg Imperial Palace in Vienna to inspire, empower and create platforms where innovation can thrive and result in profitable new business relationships. Under this year's theme of "Walk the Talks" attendees will get the chance to go beyond the technology hype while remaining firmly rooted in the reality of our future and discovering how deep-tech is redefining our world.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/